Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.
Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.
复制标题
DOI:
10.1038/srep36518
复制
发表时间:
2016-11-07
影响因子:
4.6
通讯作者:
McDonald JF
中科院分区:
文献类型:
--
作者:
Satpathy M;Mezencev R;Wang L;McDonald JF
A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies. Our results support these predictions and suggest that targeted delivery of EGFR siRNA may be an effective strategy for the treatment of ovarian and other epithelial tumors associated with elevated levels of EGFR and especially those demonstrating resistance to platinum-based therapies.
登录
查看更多内容
影响因子:
3.8
作者:
Dickerson EB;Blackburn WH;Smith MH;Kapa LB;Lyon LA;McDonald JF
通讯作者:
McDonald JF
DOI:
10.1016/j.bbrc.2012.12.070
发表时间:
2013-02-15
影响因子:
3.1
作者:
Chen, Gang;Kronenberger, Peter;De Greve, Jacques
通讯作者:
De Greve, Jacques
影响因子:
3.5
作者:
JORDAN, PA;KERNS, BJM;BERCHUCK, A
通讯作者:
BERCHUCK, A
影响因子:
--
作者:
Song, Yin-dong;Zhang, Ke-fei;Shi, Feng-jun
通讯作者:
Shi, Feng-jun
DOI:
10.1007/978-1-4939-3378-5_15
发表时间:
2016-01-01
期刊:
LONG NON-CODING RNAS: METHODS AND PROTOCOLS
影响因子:
--
作者:
Hatakeyama, Hiroto;Wu, Sherry Y.;Sood, Anil K.
通讯作者:
Sood, Anil K.